Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

R9157

Sigma-Aldrich

Ro 4-1284

≥98% (HPLC)

Synonym(e):

2-Hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,2,3,4,5,6,7-hexahydrobenzo[a]chinolizine

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H33NO3
CAS-Nummer:
303-75-3
Molekulargewicht:
347.49
MDL-Nummer:
MFCD01663028
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329824045

Assay

≥98% (HPLC)

Form

solid

Löslichkeit

DMSO: 16 mg/mL

Ersteller

Roche

Lagertemp.

2-8°C

SMILES String

CCC1(O)CC2N(CCc3cc(OC)c(OC)cc23)CC1CC(C)C

InChI

1S/C21H33NO3/c1-6-21(23)12-18-17-11-20(25-5)19(24-4)10-15(17)7-8-22(18)13-16(21)9-14(2)3/h10-11,14,16,18,23H,6-9,12-13H2,1-5H3

InChIKey

TUNMGCULOKMBNJ-UHFFFAOYSA-N

Biochem./physiol. Wirkung

Ro 4-1284 is a reversible VMAT2 inhibitor.

Leistungsmerkmale und Vorteile

This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Environment
GHS09

Signalwort

Warning

H-Sätze

H400

P-Sätze

P273

Gefahreneinstufungen

Aquatic Acute 1

Lagerklassenschlüssel

13 - Non Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

J E Leysen et al.
European journal of pharmacology, 206(1), 39-45 (1991-01-25)
[3H]Ketanserin was found to label (besides a low amount of 5-HT2 receptors) non-serotonergic binding sites on human platelet membranes. The latter binding was detected in the presence of excess of the 5-HT2 antagonist BW501, and was potently inhibited by tetrabenazine.
Innately hearing impaired Sprague-Dawley rats exhibit audiogenic seizure susceptibility following monoamine depletion.
C E Reigel et al.
Proceedings of the Western Pharmacology Society, 36, 267-271 (1993-01-01)
A Colzi et al.
The Journal of pharmacology and experimental therapeutics, 265(1), 103-111 (1993-04-01)
The effects of reversible inhibitors of monoamine oxidase-A (moclobemide, Ro 41-1049, both 20 mg/kg, i.p., and brofaromine, 10 mg/kg, i.p.) on the outflow of dopamine (DA) and its metabolites (3,4-dihydroxyphenylacetic acid and homovanillic acid) as well as of 5-hydroxyindoleacetic acid
A M Dopico et al.
Journal of neurochemistry, 61(2), 481-489 (1993-08-01)
A single dose of x-irradiation was applied on the cephalic end of newborn rats, and the alterations in the noradrenergic afferents to the cerebellum were studied 180 days later. A net increase in the noradrenaline content of cerebellum was found
E Missirlis et al.
Investigational new drugs, 8(2), 145-147 (1990-05-01)
Inhibition of angiogenesis offers an alternative approach to cancer chemotherapy, since solid tumor growth has an absolute dependency on angiogenesis. We have previously shown that 8,9-dihydroxy-7-methyl-benzo [b]quinolizinium bromide (GPA1734) is a basement membrane synthesis inhibitor, and that this compound acts
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.